About Mercury Bio
Mercury Bio develops medicines for people with Parkinson’s and Alzheimer’s. It also targets other illnesses that start inside cells. Its MB-TIP system uses tiny packages produced by yeast cells to move treatments into selected cells. Called yEVs, these packages can carry four cargo types. Examples include proteins, RNA and small-molecule drugs. Nanobodies are a type of protein cargo. The system is designed to cross the blood-brain barrier and enter neurons. It then releases cargo into cell fluid while avoiding destruction inside cellular compartments. The first pipeline programs target Parkinson’s and Alzheimer’s disease.
Mercury Bio operates in Santa Fe, New Mexico. Co-founder Bruce McCormick is chief executive officer, while Richard Sayre is chief scientific officer. Additional research receives support from Los Alamos National Laboratory through a cooperative research and development agreement.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | Nov 13, 2026 | $1,589,992fully sold | 3 | $529K | EquityRule 506(b) | Form D ↗ |
| Oct 27, 2026 | Nov 12, 2026 | $13,268fully sold | 1 | $13,268 | OptionsRule 506(b) | Form D ↗ |
| Sep 30, 2025 | Oct 24, 2025 | $2,376,107of $7.9M target | 6 | $396K | EquityRule 506(b) | Form D ↗ |
| Feb 13, 2025 | Feb 21, 2025 | $2,541fully sold | 1 | $2,541 | EquityRule 506(b) | Form D ↗ |
| Mar 7, 2024 | Apr 3, 2024 | $149,987of $2.0M target | 2 | $74,994 | Equity, OptionsRule 506(b) | Form D ↗ |
| Feb 3, 2023 | Feb 17, 2023 | $1,154,071of $3.0M target | 8 | $144K | EquityRule 506(b) | Form D ↗ |
| Oct 15, 2022 | Nov 14, 2022 | $200,000fully sold | 2 | $100K | EquityRule 506(b) | Form D ↗ |
| Total, seven offerings | $5,485,966 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
What the SEC Filings Show
- Bryan Scheer first appears as a director on the Form D that Mercury Bio filed on November 12, 2026. [12]Form D filings that name Bryan Scheer (2):
- Mercury Bio, CEO, InREACH HEALTHCARE & ADVA CERA, director: Nov 12, 2026 · Nov 13, 2026
- Paul Laur was last listed as a director on the Form D that Mercury Bio filed on October 24, 2025. [13]Form D filings that name Paul Laur (5):
- Mercury Bio, executive officer and director: Nov 14, 2022 · Feb 17, 2023 · Apr 3, 2024 · Feb 21, 2025 · Oct 24, 2025
- Alexander Koglin first appears as a director on the Form D that Mercury Bio filed on February 21, 2025. [14]Form D filings that name Alexander Koglin (12):
- Asaph, president and director: Jan 14, 2020
- NTxBio, president and director: Jan 14, 2020
- Nature's Toolbox, executive officer and director: Jan 14, 2020 · Sep 8, 2023 · Nov 22, 2023
- Ekidna, president and director: Jan 14, 2020
- Biuveris, president and director: Jan 14, 2020
- Mined Therapeutics, director: Sep 27, 2021
- Mercury Bio, director: Feb 21, 2025 · Oct 24, 2025 · Nov 12, 2026 · Nov 13, 2026
- Tuck Stibich was last listed as a director on the Form D that Mercury Bio filed on April 3, 2024. [15]Form D filings that name Tuck Stibich (3):
- Mercury Bio, director: Nov 14, 2022 · Feb 17, 2023 · Apr 3, 2024
- John Tomes first appears as a director on the Form D that Mercury Bio filed on April 3, 2024. [15]Form D filings that name John Tomes (8):
- Hydrofarm Holdings Group, director: Sep 11, 2018 · Dec 17, 2019 · Jan 14, 2020
- Mercury Bio, director of Finance, Mercury Bio: Apr 3, 2024 · Feb 21, 2025 · Oct 24, 2025 · Nov 12, 2026 · Nov 13, 2026
Who Invested in Mercury Bio
Scroll table to see all columns →
| Announced | Round | Amount | Lead | Other investors | On the Form D | Source |
|---|---|---|---|---|---|---|
| Jan 8, 2026 | Series A | Undisclosed | — | — | [4] | |
| Aug 30, 2023 | Seed | $2 million | — | Corporations and individuals from across the nation. | [8] |
Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
Why Investors Backed Mercury Bio
Mercury Bio identifies getting medicines inside neurons as the central barrier to changing Parkinson’s and Alzheimer’s disease. Large drugs must cross the blood-brain barrier and reach neuronal cell fluid without being destroyed. Its 2025 preclinical models achieved those steps, giving the investment case early technical support. [4]
“Our focus at Mercury Bio is on advancing therapeutics that address those intracellular mechanisms.”
Origin and Team
Bruce McCormick co-founded Mercury Bio. He previously co-founded and served as president of SAVSU Technologies, then led Air Guard Medical as president. [9][2]
Richard Sayre previously worked as a senior research scientist at Los Alamos National Labs. [2]
Product and Technology
Preclinical models in 2025 found that intravenous yEVs crossed the blood-brain barrier, spread through several brain regions, and entered neurons. They delivered therapeutic amounts of proteins and messenger RNA into neuronal cell fluid without endosomal degradation. [4]
MB-TIP uses AI-informed ligand design to improve cell targeting. Its engineered immunotherapeutics help select candidates and guide ligand design through disease modeling. [1]
Meta-Flux combines data from multiple biological layers with whole-disease computer simulations. It models pathway behavior and cell-state changes to guide target selection and early development decisions. [5]
As of January 8, 2026, Mercury Bio was advancing several Parkinson’s and Alzheimer’s candidates toward FDA investigational-new-drug approval. [4]
The Himed research program planned to load BMP-9 into yEV particles within a calcium phosphate scaffold. The scaffold would release those particles into nearby tissue at selected rates. [10]
Milestones
Scroll table to see all columns →
| Date | What happened | Source | Coverage |
|---|---|---|---|
| Jun 22, 2026 | Casey Perkins became chief business officer after joining Mercury Bio in December 2025. | [9] | — |
| Jan 8, 2026 | Mercury Bio launched MB-TIP, its framework for intracellular therapies. | [4] | — |
| Jan 8, 2026 | Mercury Bio launched its Series A financing round. | [4] | — |
| Dec 18, 2025 | Mercury Bio and Meta-Flux began a strategic collaboration on central nervous system drug programs. | [5] | — |
| Dec 9, 2025 | Casey Perkins joined Mercury Bio as vice president of corporate strategy and business development. | [6] | — |
| Oct 1, 2025 | Mercury Bio reported a preclinical study conducted by Vanderbilt University School of Medicine’s Simerly Lab. | [3] | — |
| Oct 1, 2024 | Alex Koglin joined Mercury Bio’s board of directors. | [7] | — |
| Jul 23, 2024 | Mercury Bio began a biomolecular study with Los Alamos National Laboratory and the University of New Mexico. The National Center for Genome Resources and University of Texas Medical Branch also joined. | [7] | — |
| Jan 23, 2024 | Mercury Bio joined the Alliance for mRNA Medicines. | [7] | — |
| Dec 20, 2023 | Mercury Bio announced plans to present its drug-delivery platform at the 2024 Biotech Showcase. | [7] | — |
| Nov 21, 2023 | Life-science tools executive Mike Rice joined Mercury Bio’s board of directors. | [7] | — |
| Aug 30, 2023 | John Tomes became Mercury Bio’s finance director. | [8] | — |
| Jul 13, 2023 | Mercury Bio and Himed entered a research agreement to develop an osteogenic material for orthopedic use. | [10] | — |
| Jun 15, 2023 | Mercury Bio received technical maturation assistance through a Los Alamos National Laboratory initiative. | [7] | — |
Market
Mercury Bio argues that symptom management leaves core disease biology untouched. It expects intracellular treatment to permit earlier intervention and reach more patients. [1]
We wrote this summary from public statements by Mercury Bio and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Mercury Bio's Form D filed Nov 13, 2026.
Earlier filings also listed Paul Laur (executive officer and director, last listed Oct 2025), Tuck Stibich (director, last listed Apr 2024) and Steve Buelow (director, last listed Feb 2023).
Sources
- CompanyMercury Bio homepage · linked above ↑
- CompanyMercury Bio team
- CompanyMercury Bio company news
- CompanyMercury Bio MB-TIP launch
- CompanyMercury Bio and Meta-Flux collaboration
- CompanyMercury Bio appoints Casey Perkins
- PressMercury Bio PR Newswire newsroom
- PressMercury Bio $2 million seed announcement
- PressMercury Bio promotes Casey Perkins
- ResearchHimed and Mercury Bio research partnership
- SECMercury Bio Form D, filed 2026-11-13 · linked above ↑
- SECMercury Bio Form D, filed 2026-11-12 · linked above ↑
- SECMercury Bio Form D, filed 2025-10-24 · linked above ↑
- SECMercury Bio Form D, filed 2025-02-21 · linked above ↑
- SECMercury Bio Form D, filed 2024-04-03 · linked above ↑
- SECMercury Bio Form D, filed 2023-02-17 · linked above ↑
- SECMercury Bio Form D, filed 2022-11-14 · linked above ↑
- SECMercury Bio, Inc. filing history